Davis Polk advised the representatives of the several underwriters in the deal. Intercept Pharmaceuticals, Inc. offered SEC-registered 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc….
Intercept Pharmaceuticals, Inc.’s $231 Million Common Stock Offering And $230 Million Convertible Senior Notes Offering
